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The use of inhaled Nitric Oxide (iNO) to treat persistent
pulmonary hypertension (PPH) in near-term and full-term
neonates significantly improves oxygenation,1,2 and it is
useful and safe.3,4 The “Equipment” section of the most
recent edition of the “Guidelines for Air and Ground
Transport of Neonatal and Pediatric Patients”5 clearly
states the need to include iNO administration equipment
among the specific recommendations for Neonatal-
Pediatric Transport. The efficacy, safety, and use of iNO
during air and ground transport have been evaluated,6,7 and
it was found that iNO can be safely delivered during
transport in a variety of ways.1 Some commercially avail-
able delivery devices are now on the market, but they have
to be adapted to various modes of transport or local regu-
lations. In this brief communication, we describe a
customized iNO therapy device for use in our Neonatal
Emergency Transport Service (NETS) in the Liguria region,
Italy.2. A device description
Our trolley for neonatal transport contains two ventilators,8
three syringe pumps, a suction unit, a multifunction
monitor, a transcutaneous monitor, a defibrillator, and four* Corresponding author. Neonatal Intensive Care Unit, Neonatal
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for air. The weight of the trolley as per this set up, that
includes the transport bag, averages approximately 170 kg
(375 pounds). When we decided to improve the quality of
our NETS, fitting it with an iNo device, we mainly took into
consideration what device(s) was/were available and the
effects of the increase in the weight on trolley handling.
Currently, in Italy, the only available delivery system is the
iNOmax transport system (INO Therapeutics LLC d/b/a
Ikaria, Inc., NJ, USA, available at: http://inomax.com/wp-
content/uploads/2015/01/20010_rev_05_INOmax_DSIR_
Operation_Manual_with_Links.pdf). The INOmax system
weighs approximately 15 kg (33 pounds), thus increasing
the total trolley weight to approximately 185 kg (400
pounds), i.e., increasing both the weight (approximately
9%) and the handling difficulties with the trolley. A
further important consideration was to imagine the
possible number of transports per year that might
potentially require iNO therapy. PPH is estimated to
affect around 10,000 full-term and near-term neonates in
the USA annually, calculated on a birth rate of around 4
million births (2013) (http://www.cdc.gov/nchs/fastats/
births.htm), and the prevalence of PPH has been
estimated at around 1.9 per 1000 live births based on
71,558 newborns with a broad variation observed among
the centers (0.43e6.82 per 1000 live births).3,9 In Italy,
epidemiological data are currently not available; we have
experienced no more than 2e3 cases per year during the
last five years of NETS activity. These figures, in our
opinion, do not warrant keeping the iNO device perma-
nently assembled in the transport trolley. Thus, we decided
to build a semi-permanent device mounted inside theElsevier Taiwan LLC. This is an open access article under the CC BY-
Fig. 1 Upper panel: A schematic diagram showing the device assembly. Lower panel, from left to right: The device not in use, as
stored inside the ambulance; then set up for use in the ambulance; and finally, when the trolley is ready to be moved from the
ambulance. 1 and 2: Air and oxygen ambulance spares, respectively (three 10-L cylinders each). 3: NO cylinders (an iNOmax de-
vice). 4 and 5: Air and oxygen neonatal transport incubator spares, respectively (two 3-L cylinders each). 6: Fixed gas connections
in the ambulance. 7: Gas connections on the neonatal transport incubator. A: An oxygen line to the ventilator. B: An oxygen source
to the iNO blender. C: A NO line to the iNO blender. D: An optional second oxygen line to the second ventilator (for twins only). E: A
split oxygen line to be used optionally for twins or for iNO therapy. F: An airline to the ventilator. G: An optional second airline to
the second ventilator (for twins only). H: A line to the patient from the ventilator. Note: Turn the iNO blender setting dial to the
delivered concentration (15e20 ppm); turn the oxygen flow-meter to the flow rate 5e14 L/min; before connecting to the patient,
and be sure to purge the NO2 from the system.
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during transport, may be immediately and easily moved
from the ambulance and transferred onto the trolley only if
and when necessary and without any interruption of the
iNO administration. This way, iNO therapy is always avail-
able, but at the same time, the trolley is free from the
burden and weight of the iNO device. This “custom” system
is shown in the Fig. 1 (see the legend for complete details).3. Discussion
In our regional setting of perinatal care, iNO therapy is not
available at all of the referring hospitals. We consider our
solution to be safe, cheap, and appropriate in our specific
setting on the basis of specific conditions, including the fact
that a) the 2 l size “iNOmax” cylinder at 155 bar will deliver
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10 l per minute; b) in our geographical setting, the longest
transport may average approximately 3 h; c) although we
can expect no more than 2e3 cases per year on the basis of
our prior NETS activity, by applying the device proposed
herein, we can be ready at any time to deal with patients
who unexpectedly need iNO therapy during transport; d)
the proposed method complies with local regulations; e) a
specific training and practice program has been completed
with this system; and f) by moving the iNOmax device from
the ground ambulance to the neonatal transport incubator,
it can be used in the helicopter. Previous experience by
Kinsella et al.,6 who evaluated the effects of the possible
accidental release of NO into the transport vehicle by
simulating the catastrophic release of the entire NO cylin-
der into the transport vehicle, led to the conclusion that NO
and NO2 concentrations remained within safe ranges during
transport even in vehicles (fixed wing and rotor wing
aircraft, and ground vehicles) with no air exchange. The
portable device described herein is certified and authorized
for use in Italy; no specifications have been provided on
“how” we must use the device, i.e., if it has to be anchored
to the ambulance, or to the trolley, or other possibilities.
Thus, our article describes how we have tried to solve the
problem; the suggested solution is certainly feasible within
the limits of the Italian law. A variety of regulations are
surely present in other countries and the readers must be
warned that this solution may not be allowed in other/some
countries. We believe that iNOmax in transport is not
considered “off-label” in Italy or in countries in which
iNOmax has been certified. We believe that how each in-
dividual transport service decides to carry the device does
not influence its correct use.In conclusion, we believe that the proposed device may
be a satisfactory solution in cases of low annual iNO therapy
use in neonatal transport, avoiding the risk of overloading
the transport trolley while being sure of the possibility to
treat severely affected newborns at any time.
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